University of Cambridge

Minister calls for UK to turn startup strength into scaleup success at Oxford-Cambridge Innovation Showcase

Cambridge Enterprise

Chris McDonald MP called on investors to back UK innovation, as companies from the Oxford-Cambridge corridor showcased to investors.

Together with Oxford University Innovation, Cambridge Enterprise hosted the second Oxford-Cambridge Innovation Showcase on Monday night, bringing together investors, founders and partners to hear from 20 companies from two of the world’s leading innovation ecosystems.

Opening the event, Chris McDonald MP, Minister of State, Department for Business, Innovation, Science and Trade and Minister for State, Department of Health and Social Care, said the UK’s challenge is no longer creating exciting companies but helping more of them grow into globally competitive businesses from the UK.

The Minister said: “We’ve been good at inventing things, but often the discoveries made in British laboratories have gone on to create businesses, industries and jobs somewhere else. I want to see more of those companies starting here, growing here, staying here, being successful in the United Kingdom. I want to see the benefits of British science, both the economic benefits and the improvements to people’s lives, felt right across the country.”

The Minister described Oxford and Cambridge as “the world’s greatest centres for scientific discovery”, adding that their strength goes beyond the universities themselves; around them have grown the entrepreneurs, investors and businesses that turn ideas from the laboratory into technologies, new companies and improvements in people’s lives.

Referring to the government’s commitment to and its “record levels of investment” in supporting the growth of UK innovation, the Minister called on investors to recognise the potential of the world-class science and brilliant entrepreneurs translating these discoveries.

“The next generation of British life science companies will not emerge solely as a result of government policy. They’ll emerge from the science that’s taking place in our universities, the ambition of the people who want to turn that science into something useful, and from the investors who are prepared to back them.”

Shaun Grady, Chair of AstraZeneca UK, endorsed the Minister’s call for the UK to turn its scientific strengths into companies that scale. Referencing the opportunity demonstrated across the Oxford-Cambridge corridor, the Northern Arc, Edinburgh, Glasgow and other clusters, he said

“Excellent science is necessary, but it’s no longer enough on its own. The task is to make sure all three of these things are in place: academic excellence, a strong business environment and valuing and adopting innovation. In the UK, we have a real opportunity to be world-leading, with Oxford, Cambridge and the corridor between us as one of the strongest life science clusters anywhere in the world. Oxford and Cambridge show what the UK can offer.”

Dr Jim Glasheen, Chief Executive of Cambridge Enterprise, said:

“Twenty companies, two ecosystems, one shared ambition: turning world-class research into companies that change lives. Oxford and Cambridge have world-class science and ambitious founders.”

Dr Mairi Gibbs, Chief Executive of Oxford University Innovation, said:

“The Oxford-Cambridge Growth Corridor represents an extraordinary opportunity to strengthen the UK’s position as a global leader in innovation. Our ecosystems bring together exceptional research, entrepreneurial ambition and the expertise needed to translate knowledge and research into real-world applications.”

Together, Oxford and Cambridge offer an exceptional concentration of research, entrepreneurship, talent, and investment opportunity. The corridor has the potential to make a significant contribution to UK economic growth, with estimates of £78bn by 2035. Recent funding shows the confidence in these ecosystems. In the last month , $443 million has been raised by two companies alone: Oxford spinout OMASS Therapeutics raised $310 million in an oversubscribed Series C round, and Cambridge spinout T-Therapeutics secured $133 million in an oversubscribed Series B round.

The strength of scientific discovery was also evident in the companies presenting on the night, with opportunities from pre-seed to Series B in areas including RNA therapeutics to restore hearing, an oral treatment for Huntington’s disease, cancer vaccines in clinical trials and a rapid stroke blood test already in use in more than 280 London ambulances.

The event was sponsored by HGF and Penningtons Manches Cooper, and supported by Babraham Research Campus, AstraZeneca, Wellcome Genome Campus, Cambridge Innovation Capital, Innovate Cambridge and o2h discovery.

Presenting companies

CamGene Therapeutics | Cambridge

CellCodex | Cambridge

ExpressionEdits | Cambridge

FunctionRx | Cambridge

Gastrobody Therapeutics | Cambridge

Granza Bio | Oxford

Infinitopes | Oxford

Ion Therapeutics | Oxford

ISOgenix | Oxford

Marley Health | Oxford

New Path Molecular Research | Cambridge

Nuanced Bio | Oxford

Oxford Endovascular | Oxford

Pelvic Matters | Oxford

RevoNA Bio | Cambridge

Safer Birth | Oxford

Scripta Therapeutics | Oxford

T-Therapeutics | Cambridge

Theolytics | Oxford

Upfront Diagnostics | Cambridge

Image credits: David Johnson Photographic 2026